American Society of Clinical Oncology (ASCO)

The American Society of Clinical Oncology (ASCO) is a professional organization representing physicians of all oncology sub-specialties who care for people with cancer. Founded in 1964 by Fred Ansfield, Harry Bisel, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane C. Wright, it has nearly 45,000 members worldwide.

PD-L1, PD-1, and CTLA-4 as Prognostic Biomarkers in Resected NSCLC

ASCO 2015 – Lung Cancer

ASCEND-3: a Phase 2 Study of Ceritinib in ALK Inhibitor-Naïve Adult Patients with ALK+ NSCLC

ASCO 2015 – Lung Cancer

GASTO 1001: a Phase 2 Trial of Neoadjuvant Bevacizumab plus Pemetrexed and Carboplatin in Patients with Unresectable Stage III Lung Adenocarcinoma

ASCO 2015 – Lung Cancer

Final Follow-up Results from RADIANT: Adjuvant Erlotinib Vs Placebo Following Complete Tumor Resection in Patients with Stage IB–IIIA EGFR-positive NSCLC

ASCO 2015 – Lung Cancer

A Mutant-Selective EGFR Inhibitor in NSCLC

ASCO 2014 – Lung Cancer

Phase 2 Trial of Nivolumab and VEGF Inhibitors in First-Line Metastatic Renal Cell Carcinoma

ASCO 2014 – Immuno-Oncology

MPDL3280A, an Anti-PD-L1 Monoclonal Antibody, in Metastatic Bladder Cancer

ASCO 2014 – Immuno-Oncology

Pharmacokinetics of MEDI4736, an Anti-PD-L1 Monoclonal Antibody, in Advanced Solid Tumors

ASCO 2014 – Immuno-Oncology

Immuno-Oncology: The New Frontier?

ASCO 2014 – Immuno-Oncology

Ipilimumab Combined with Cytotoxic Chemotherapy in Metastatic Melanoma

ASCO 2014 – Immuno-Oncology

Page 25 of 31

22
23
24
25
26
27
28

Conference Coverage Proudly Presented by

American Health & Drug Benefits

Journal of Hematology Oncology Pharmacy

Journal of Oncology Navigation & Survivorship

Oncology Practice Management

Personalized Medicine in Oncology

The Oncology Nurse–APN/PA

The Oncology Pharmacist

Value-Based Cancer Care

Learn more about our family of publications.

View Our Publications